WIPO has published 2 studies on inventive step and sufficiency of disclosure in patent laws.
ACIP now recommends abolition of the innovation patent system
Having had the interlocutory injunction he granted overturned on appeal, Rares J has now determined at the substantive trial that both of Glaxo’s syringe variants infringed Reckitt Benkiser’s “flat-nosed syringe” patent.
Sanofi sued Apotex (then known as GenRx) for infringement of its “clopidogrel patent”. It obtained interlocutory injunctions against Apotex against the sale of Apotex’ product and preventing Apotex from applying to list its product under the Pharmaceutical Benefits scheme (PBS). As a condition of the grant of those interlocutory injunctions, Sanofi gave the “usual undertaking as to damages”: “(a) submit to such order (if any) as the Court may consider to.. Read More
IP Australia has released the Australian Intellectual Property Report 2015, with statistics on IP filings and grants and trends.
The High Court has allowed special leave to appeal from the Full Federal Court’s decision in AstraZeneca v Apotex (“Rosuvastatin”).
The Full Court has clarified what the prior use must disclose for it to be novelty destroying under the Patents Act 1990
Beach J accepted that springboard injunctions are available for patent infringement, but refused the grant on the facts.
Flick J rules that Pfizer did not breach antitrust rules by trying to maintain sales of Lipitor after it came off patent.
P Australia has issued consultation papers on removing red tape and other streamlining options